Releuko Filgrastim-Ayow Injection 300mcg/0.5 mL Prefilled Syringes 27 gauge x 1/2 inch Needle **Refrigerated (RX)

Advanced White Blood Cell Support with FDA-Approved Releuko® Filgrastim-ayow

Releuko® (filgrastim-ayow) Injection is a highly trusted, FDA-approved biosimilar to Neupogen® (filgrastim), designed to boost neutrophil (white blood cell) production for patients at risk of neutropenia, especially during chemotherapy, bone marrow transplant, or other cancer treatments. Each prefilled syringe contains a precise dose of 300mcg/0.5 mL—equipped with an ultra-thin 27 gauge x 1/2” needle—to ensure accurate, virtually painless administration.

Indications & Clinical Use

• Chemotherapy-Induced Neutropenia: Reduces infection risk and neutropenia duration in cancer patients receiving myelosuppressive chemotherapy.
• Bone Marrow & Stem Cell Transplantation: Aids in the mobilization and recovery of hematopoietic stem cells.
• Severe Chronic Neutropenia: For patients with congenital, cyclic, or idiopathic neutropenia to maintain safe neutrophil levels.
• Cancer Supportive Therapy: Assists oncology teams in improving treatment initiation and maintenance by minimizing chemotherapy delays due to low ANC.

Health Benefits & Key Clinical Features

• Rapid Neutrophil Recovery: Clinically proven to raise absolute neutrophil count (ANC) and decrease the duration of severe neutropenia.
• Reduces Risk of Infection: Minimizes life-threatening infections in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy or undergoing bone marrow or stem cell transplantation.
• Biosimilar Efficacy & Affordability: Offers the same safety, strength, and potency as Neupogen® at a lower cost—improving access to advanced oncology care.
• Prefilled Syringe Convenience: Designed for ease of use, safer dosing, and accurate self-administration by patients or caregivers at home or in the clinic.
• Latex-Free, Ready-to-Use: Sterile, single-dose prefilled syringes reduce preparation errors and cross-contamination risk.
• Backed by Amneal Quality: Manufactured under strict GMP standards for optimal purity, safety, and reliability.

Why Choose Releuko® by Amneal BioServices?

• Affordable Biosimilar: FDA-approved alternative, ensuring access to cost-effective, high-quality biologic therapy.
• Single-Dose Precision: Each prefilled syringe delivers an accurate 300 mcg dose, simplifying the injection process and minimizing dosing mistakes.
• Patient-Focused Design: Ultra-fine 27G x 1/2” needle is designed for patient comfort and minimal injection pain.
• Reliability & Safety: Amneal’s world-class manufacturing ensures a product that meets strict quality, sterility, and efficacy standards.

Dosage & Administration

• Strength: 300mcg/0.5mL
• Route: Subcutaneous or intravenous injection
• Needle: 27 gauge x 1/2 inch
• Instructions: To be administered by a healthcare provider or as directed in your treatment plan. Refer to full Prescribing Information for dosing protocols by indication.

Important Compliance & Product Details

• Brand: Releuko® (filgrastim-ayow), Amneal BioServices
• NDC: 70121-1568-01
• UPC: 370121156819
• Formulation: Prefilled syringes, latex-free
• Strength per Syringe: 300mcg/0.5 mL
• Includes: 27G x 1/2" needled syringes, packaging for safe transport and storage

Support Your Oncology Journey with Trusted Releuko® Injection

Releuko® (filgrastim-ayow) Injection is a leader in cancer supportive care, helping patients maintain healthier white blood cell counts and continue their treatment journey stronger and safer. Choose Releuko or recommend it to your care team for advanced infection prevention, optimized neutrophil recovery, and comprehensive oncology support.